InnoCare Gets Green Light for Clinical Trial of New Cancer Drug ICP-B794 in China

Innocare’s Received Approval for a Clinical Trial in China

Image Credits: BioWorld

Announcement

Innocare Pharma, a global biopharmaceutical company known for its advanced treatment for autoimmune diseases and cancer, received approval of an IND Investigational New Drug by the CDE Center for Drug Evaluation of the NMPA China National Medical Products Administration for organizing a clinical trial of B7-H3 targeted ADC ICP-B794. The enhancement and advancement in cancer treatment are highly valued in the healthcare market. The availability and access of the drug (therapy) in extreme conditions are acknowledged to improve the patient outcome. The technology has fueled the trial and new development in the healthcare sector.

Clinical Trial

The ICP-B794 is an ADC comprising a potent in-house developed payload to humanized anti-B7-H3 monoclonal antibody conjugated through a protease-cleavable linker. This integration focuses on precision tumor cells by reducing off-target effects, which will provide an effective treatment for solid tumors like neck squamous cell carcinomas, esophageal cancer, lung cancer, nasopharyngeal cancer, and prostate cancer.

Recently, B7-H3 therapy is not yet available and approved for commercialization globally. B7-H3 is a type 1 transmembrane protein that is found in various solid tumors. The effectiveness of this therapy will prove the potential of its anti-tumor target. The approval of the clinical trial will prove the safety and efficacy of the drug (treatment). Further, the trial will lead to the introduction of a new treatment in China.

Efforts

Innocare, with its strong competitive drug portfolio and its commitment to treat a vast range of solid tumor indications, has added efforts to develop its combinational therapies via ADC technology. The Research and Development team is aiming to develop and discover a platform that will provide solutions to the solid tumors and use innovative technologies to address and advance drug candidates, enabling clinical benefits. The company’s ADC technology platform and precision medicine candidates, such as TRK inhibitor zuletrectinib (ICP-723), have encouraged the company to build a strong presence in the solid tumor treatment area.

Views and Statements

Co-Founder, Chairwoman, and CEO of Innocare, Dr. Jasmine Cui, said, “ICP-B794 has been initiated via the company’s proprietary ADC platform. This platform is built to integrate ADC with an accurate therapeutic window and tumor-killing efficacy. By introducing treatment options for cancer patients, we will be able to elevate patient outcomes. This platform is a milestone for the company that helps to expand the portfolio with various differentiated ADC candidates, also an advancement to oncology medicine.”